Log in

Relevant bibliographies by topics / Bepotastine / Journal articles

To see the other types of publications on this topic, follow the link: Bepotastine.

Journal articles on the topic 'Bepotastine'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Bepotastine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Malahat, Amatur R., Sudhakar Kodudula, and Vijaya L. Gali. "A prospective comparative study to evaluate the efficacy and safety of olopatadine eye drops and bepotastine eye drops in subjects of vernal kerato conjunctivitis." International Journal of Basic & Clinical Pharmacology 9, no. 5 (2020): 706. http://dx.doi.org/10.18203/2319-2003.ijbcp20201743.

Full text

Abstract:

Background: Vernal keratoconjunctivitis (VKC) is an allergic eye disease that especially affects young boys. Both olopatadine and bepotestine are dual acting drugs that provide rapid symptomatic relief coupled with the long-term disease-modifying benefit. The present study is conducted to compare the efficacy and safety of olopatadine eye drops and bepotastine eye drops in patients of vernal keratoconjunctivitis.Methods: A prospective, randomized, parallel-group, comparative study is conducted over a period of 4 weeks on paediatric patients with VKC. 50 patients are recruited and randomized in

APA, Harvard, Vancouver, ISO, and other styles

2

Lyseng-Williamson, Katherine A. "Oral Bepotastine." Drugs 70, no. 12 (2010): 1579–91. http://dx.doi.org/10.2165/11205880-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Prashant, Kumar, and Verma Anurag. "Comparative Research on the Effectiveness and Safety of LongActing Antihistamines in Allergic Conjunctivitis in Indian Patients: An RCT Trial." International Journal of Pharmaceutical and Clinical Research 13, no. 4 (2021): 181–87. https://doi.org/10.5281/zenodo.14201914.

Full text

Abstract:

<strong>Aim:</strong> The aim of the present study was to compare the safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. <strong>Methods:</strong> A total of 90 patients with mild or moderate allergic conjunctivitis were randomized into three groups with an allocation ratio of 1:1:1 using computer-generated random number sequence to receive topical anti-allergic medication for 14 days as Group 1: Topical 0.25% Alcaftadine eye drops OD, Group 2: Topical 0.2% Olopatadine eye drops OD and Group 3: Topic

APA, Harvard, Vancouver, ISO, and other styles

4

Mrinalini, C. Damle* and Shital P. Ghode. "STABILITY INDICATING CHROMATOGRAPHIC METHOD FOR ESTIMATION OF BEPOTASTINE BESILATE." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 06 (2018): 5222–28. https://doi.org/10.5281/zenodo.1289735.

Full text

Abstract:

A Simple, rapid, stability indicating HPTLC method has been developed for estimation of bepotastine besilate. HPTLC separation was carried out on Merck TLC aluminium sheets precoated with silica gel 60F254 using mobile phase as chloroform : methanol. Bepotastine besilate gave sharp peak at RF 0.53 ±0.03 at 225nm.calibration curve was linear in range 5-25ug/band for bepotastine besilate. Stress degradation study was carried out according to ICH guidelines Q1A (R2) and the method was validated as per ICH guideline.

APA, Harvard, Vancouver, ISO, and other styles

5

Damle, M. C., and K. K. Pardeshi. "Development of Analytical Method to Monitor Dissolution of Bepotastine Besilate Tablet." Journal of Drug Delivery and Therapeutics 9, no. 4 (2019): 251–56. http://dx.doi.org/10.22270/jddt.v9i4.3037.

Full text

Abstract:

Bepotastine Besilate is an anti-histaminic drug and it is marketed as tablet of strength 10mg. In this study an attempt is made to monitor the dissolution of Bepotastine Besilate tablet. Dissolution study was done for marketed sample using phosphate buffer 6.8, phosphate buffer 4.5 and 0.1 N HCl as dissolution media. Samples were analysed using UV spectrophotometer, HPLC and HPTLC. Detection wavelength selected was 226nm. A chromatographic separation is achieved on a C18 column with a mobile phase consisting of acetonitrile, water with isocratic elution with flow rate 1ml/min. Solvents used fo

APA, Harvard, Vancouver, ISO, and other styles

6

Renuka, Ranjan Alok, and Kumar Sinha Ajay. "Comparative Assessment of Alcaftadine 0.25%, Olopatadine Hydrochloride 0.2% and Bepotastine Besilate 1.5% as AntiAllergic Conjunctivitis Agents." International Journal of Pharmaceutical and Clinical Research 13, no. 6 (2021): 412–19. https://doi.org/10.5281/zenodo.14218171.

Full text

Abstract:

<strong>Aim:</strong> The aim of the present study to compare the safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. <strong>Methods: </strong>A total of 90 patients with mild or moderate allergic conjunctivitis were randomized into three groups with an allocation ratio of 1:1:1 using computer‑generated random number sequence to receive topical anti-allergic medication for 14 days as Group 1: Topical 0.25% Alcaftadine eye drops OD, Group 2: Topical 0.2% Olopatadine eye drops OD and Group 3: Topical 1

APA, Harvard, Vancouver, ISO, and other styles

7

Sudipto Chatterjee, Vijendra R, Soumyadeep Mahapatra, and Kiran Kumar L. "A comparative study of efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye drops in allergic conjunctivitis in a tertiary care hospital of the southern part of India." Asian Journal of Medical Sciences 15, no. 10 (2024): 9–14. https://doi.org/10.71152/ajms.v15i10.4136.

Full text

Abstract:

Background: Allergic conjunctivitis is increasing with the rise in the levels of allergens. Drug therapy is usually needed in addition to avoidance of general allergens to treat this condition. Both bepotastine besilate and olopatadine hydrochloride ophthalmic solutions are newer additions in the treatment of allergic conjunctivitis having dual properties of second-generation antihistaminics along with mast cell stabilizing activity. Aims and Objectives: The aim of the study was to compare the efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye dro

APA, Harvard, Vancouver, ISO, and other styles

8

Sudipto Chatterjee, Vijendra R, Soumyadeep Mahapatra, and Kiran Kumar L. "A comparative study of efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye drops in allergic conjunctivitis in a tertiary care hospital of the southern part of India." Asian Journal of Medical Sciences 15, no. 10 (2024): 9–14. http://dx.doi.org/10.3126/ajms.v15i10.67247.

Full text

Abstract:

Background: Allergic conjunctivitis is increasing with the rise in the levels of allergens. Drug therapy is usually needed in addition to avoidance of general allergens to treat this condition. Both bepotastine besilate and olopatadine hydrochloride ophthalmic solutions are newer additions in the treatment of allergic conjunctivitis having dual properties of second-generation antihistaminics along with mast cell stabilizing activity. Aims and Objectives: The aim of the study was to compare the efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye dro

APA, Harvard, Vancouver, ISO, and other styles

9

Kitaba, Shun, Hiroyuki Murota, Yoko Yahata, Hiroaki Azukizawa, and Ichiro Katayama. "Novel Functional Aspect of Antihistamines: The Impact of Bepotastine Besilate on Substance P-Induced Events." Journal of Allergy 2009 (June 21, 2009): 1–7. http://dx.doi.org/10.1155/2009/853687.

Full text

Abstract:

Besides histamine, substance P (SP) has been demonstrated to play a crucial role in pruritic skin diseases. Although antihistamines are frequently used for pruritic skin diseases, little is known concerning the effect on an SP-induced event such as mast cell degranulation and the upregulation of adhesion molecules or the nitric oxide (NO) synthesis in endothelial cells. Our aim was to study the effect of bepotastine besilate on SP-induced degranulation of rat basophillic leukemia (RBL-2H3) cells and expression of adhesion molecules and NO synthesis in human dermal microvascular endothelial cel

APA, Harvard, Vancouver, ISO, and other styles

10

Gupta, Priya, Seema Baishnab, and Parveen Rewri. "Comparative evaluation of efficacy and safety of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.1% ophthalmic solution in patients with vernal keratoconjunctivitis." International Journal of Basic & Clinical Pharmacology 10, no. 5 (2021): 552. http://dx.doi.org/10.18203/2319-2003.ijbcp20211652.

Full text

Abstract:

Background: Vernal keratoconjunctivitis (VKC) is a chronic, seasonally exacerbated, allergic ocular inflammation. It affect children and young adults and has male predominance. The first line of treatment often used is dual acting drugs like olopatadine and bepotastine. It combine the immediate histamine receptor antagonism, coupled with mast cell stabilization with other anti-inflammatory properties. The present study was conducted to compare the efficacy and safety of olopatadine 0.1% and bepotastine 1.5% eye drops in VKC patients.Methods: This was a prospective, open label, randomized and c

APA, Harvard, Vancouver, ISO, and other styles

11

Jyoti, Kumar Sachin, Karak Pradeep, and Rajnandani. "Randomized Clinical Parallel Trial Comparing Safety and Efficacy of Alcaftadine 0.25%, Olopatadine Hydrochloride 0.2% and Bepotastine Besilate 1.5% in Allergic Conjunctivitis." International Journal of Current Pharmaceutical Review and Research 15, no. 10 (2023): 77–82. https://doi.org/10.5281/zenodo.11618320.

Full text

Abstract:

AbstractAim: The aim of the present study was to compare the efficacy and safety of Alcaftadine 0.25%, Olopatadinehydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergicconjunctivitis.Methods: The study was an observer‑masked, randomized, prospective, parallel‑group study conducted at theDepartment of Ophthalmology for 18 months. A total of 270 patients were screened for the study, of whom 240patients with mild or moderate allergic conjunctivitis, who met the required inclusion were enrolled in the study.Results: In the present study, male was predom

APA, Harvard, Vancouver, ISO, and other styles

12

Chudiwal, V. S., S. Shahi, and S. Chudiwal. "DEVELOPMENT OF SUSTAINED RELEASE GASTRO-RETENTIVE TABLET FORMULATION OF BEPOTASTINE BESILATE USING QUALITY BY DESIGN (QBD) APPROACH." INDIAN DRUGS 54, no. 09 (2017): 48–60. http://dx.doi.org/10.53879/id.54.09.11141.

Full text

Abstract:

The objective of the present study was to develop sustained release gastro-retentive (SRGR) tablet formulation of bepotastine besilate for once-a-day dosing using quality by design (QbD) approach. Quality target product profile (QTPP) of bepotastine besilate SRGR tablet formulation was defined and critical quality attributes (CQAs) were identified. Potential risk factors were identified using fish bone diagram and failure mode effect analysis (FMEA) tool and screened by Plackett–Burman design and finally bepotastine besilate SRGR tablet formulation was optimized using Box–Behnken design. It wa

APA, Harvard, Vancouver, ISO, and other styles

13

Kim, Kyoung-Ah, and Ji-Young Park. "Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects." Clinical Drug Investigation 33, no. 12 (2013): 913–19. http://dx.doi.org/10.1007/s40261-013-0140-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rai, Ashish, Shital Poojary, Lily Dubey, and Pawan Gupta. "A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria." National Journal of Physiology, Pharmacy and Pharmacology 12, no. 8 (2022): 1. http://dx.doi.org/10.5455/njppp.2022.12.062871202217062022.

Full text

Abstract:

Background: Second generation antihistamines are first line therapy for chronic spontaneous urticaria (CSU). Sedation has been always a concern as a side effect of antihistamine for both patients and treating dermatologist. It is always better to prefer non-sedative antihistamine for CSU. Bepotastine is such promising non-sedative agent. Aim and Objectives: The objective of the study was to compare the efficacy and safety of bepotastine and levocetirizine in patients of CSU. Materials and Methods: This is a double arm, open label, randomized, and controlled study. Out of 99 patients, 50 patien

APA, Harvard, Vancouver, ISO, and other styles

15

Priyanka, A. T., K. R. Mamatha, and G. M. Puttamadaiah. "A comparative study to assess the efficacy and safety of bepotastine and cetirizine in allergic rhinitis." International Journal of Basic & Clinical Pharmacology 8, no. 10 (2019): 2304. http://dx.doi.org/10.18203/2319-2003.ijbcp20194276.

Full text

Abstract:

Background: Pharmacotherapy is the mainstay of allergic rhinitis and many caregivers use over-the-counter antihistamines. Bepotastine is a novel oral second generation non-sedative antihistamine and an effective treatment option for allergic rhinitis. The objectives of the present study were to evaluate the efficacy and safety of bepotastine versus cetirizine an over the counter drug.Methods: A prospective, randomized, open-label, parallel-group study was conducted among 60 patients fulfilling the inclusion and exclusion criteria. Group A (n=30) received tablet cetirizine 10 mg once daily and

APA, Harvard, Vancouver, ISO, and other styles

16

V. Manekar, Archana, and Sharayu Ashok Bhore. "A Comparative Study of Olopatadine Hydrochloride and Bepotastine Besilate in the Treatment of Allergic Conjunctivitis." International Journal of Research and Review 9, no. 3 (2022): 166–72. http://dx.doi.org/10.52403/ijrr.20220320.

Full text

Abstract:

Background -Ocular allergy is a commonly encountered pathology in clinical practice, which often is under diagnosed and consequently undertreated. These are rarely vision-threatening but can significantly decrease the quality of life for patients. Olopatadine and Bepotastine eyedrop have both antihistaminic and mast cell stabilization action. Their use can control acute symptoms and prevent relapses as well. We conducted this single blinded trial directly comparing the efficacy of the two topical anti allergic medications in mild forms of allergic conjunctivitis. Materials and Methods - A sing

APA, Harvard, Vancouver, ISO, and other styles

17

Askarkar, Sonali Suresh, and Krishna Radheshyam Gupta. "Design and Evaluation of Ophthalmic Delivery of Bepotastine Besilate From Eye Drop." Pharmaceutical Methods 7, no. 2 (2016): 104–15. https://doi.org/10.5281/zenodo.14857809.

Full text

Abstract:

Introduction: The purpose of present study was to design and evaluate bepotastine besilate ophthalmic solution 1.5% to develop a stable formulation using buffering agent, tonicity modifier and preservative. Method: In this study the concentration of preservative and tonicity modifier concentration are adjusted in such a way so that the final formulation will have least concentration of preservative still it will be protected from microorganisms and isotonic so that after instillation when formulation will come in contact with tissues there should not be any swelling, contraction or discomfort.

APA, Harvard, Vancouver, ISO, and other styles

18

Han, C. Q., Y. Y. Xia, Q. Sun, and Q. G. Zou. "Improved Synthesis of Bepotastine Besilate." Organic Preparations and Procedures International 53, no. 2 (2021): 206–10. http://dx.doi.org/10.1080/00304948.2020.1868930.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lee, Byung-Mu, Jung-Dae Lee, Duck-Soo Lim, et al. "Comparison of efficacy and bioequivalence between bepotastine/nicotinate and bepotastine/salicylate of antihistamine drugs." Toxicology Letters 229 (September 2014): S102. http://dx.doi.org/10.1016/j.toxlet.2014.06.375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Manoj, Kumar Mishra, Kumari Vaidehi, and K. Singh R. "A Comparative Study of Efficacy of Topical Olopatadine (0.1%), Bepotastine (1.5%) and Alcaftadine (0.25%) in Mild to Moderate Allergic Conjunctivitis at Sri Krishna Medical College, Muzaffarpur, Bihar, India." International Journal of Pharmaceutical and Clinical Research 14, no. 8 (2022): 553–59. https://doi.org/10.5281/zenodo.13357491.

Full text

Abstract:

<strong>Objectives: </strong>This study was to compare the safety and efficacy of topical Olopatadine (0.1%), Bepotastine (1.5%) and Alcaftadine (0.25%) in mild to moderate allergic conjunctivitis at Sri Krishna Medical College, Muzaffarpur, Bihar, India. <strong>Methods: </strong>All of the 150 cases were divided into three groups. Each group had 50 cases of allergic conjunctivitis. Group A: Patients were received topical 0.25% Alcaftadine eyedrops OD. Group B: Patients were received topical 0.2% Olopatadine eyedrops OD and Group C: Patients were received topical 1.5% Bepotasti

APA, Harvard, Vancouver, ISO, and other styles

21

Cho, Kwan Hyung, and Han-Gon Choi. "Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs." Drug Development and Industrial Pharmacy 39, no. 6 (2012): 901–8. http://dx.doi.org/10.3109/03639045.2012.717295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Yoon, Sukyong, Byung Hak Jin, Choon Ok Kim, Kyungsoo Park, Min Soo Park, and Dongwoo Chae. "Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria." Pharmaceutics 16, no. 3 (2024): 334. http://dx.doi.org/10.3390/pharmaceutics16030334.

Full text

Abstract:

Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propose an optimal dosing regimen for pediatric patients based on population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models using data from two previous trials. A popPK model was built using NONMEM software. A one-compartment model with first-order absorption and absorption lag time described our data well, with body weig

APA, Harvard, Vancouver, ISO, and other styles

23

Kumari, Neeti, and Kiran Godse. "Bepotastine besilate: A novel anti-histamine." Indian Journal of Drugs in Dermatology 3, no. 2 (2017): 64. http://dx.doi.org/10.4103/ijdd.ijdd_22_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bielory, Leonard, Shubhasree Duttachoudhury, and Andrea McMunn. "Bepotastine besilate for the treatment of pruritus." Expert Opinion on Pharmacotherapy 14, no. 18 (2013): 2553–69. http://dx.doi.org/10.1517/14656566.2013.849242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hussar, Daniel A., and Cheryl A. Abbas. "New drugs: Asenapine, iloperidone, and bepotastine besilate." Journal of the American Pharmacists Association 50, no. 1 (2010): 107–10. http://dx.doi.org/10.1331/japha.2010.10505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Saurabh, Tripathi, Nidhi, and Kumar Amresh. "Comparative Study of Efficacy of Topical Olopatadine (0.1%), Bepotastine (1.5%) and Alcaftadine (0.25%) in Mild to Moderate Allergic Conjunctivitis." International Journal of Current Pharmaceutical Review and Research 15, no. 08 (2024): 363–67. https://doi.org/10.5281/zenodo.12566923.

Full text

Abstract:

AbstractAim: The aim of the present study was to compare the efficacy and safety of Alcaftadine 0.25%, Olopatadinehydrochloride 0.1%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergicconjunctivitis.Methods: A prospective study was conducted on 210 patients of allergic conjunctivitis visiting Department ofOphthalmology of a tertiary care hospital in south Bihar after random selection. Randomly generated treatmentregimens were sealed within opaque envelopes and were allocated to the patients after obtaining their informedconsent. A total of 210 patients were enrolle

APA, Harvard, Vancouver, ISO, and other styles

27

Kim, Bo-Hyung, Jae-Yong Chung, Jung-Ryul Kim, et al. "Pharmacokinetic Characteristics of Bepotastine Besilate in Healthy Subjects." Journal of Korean Society for Clinical Pharmacology and Therapeutics 15, no. 1 (2007): 37. http://dx.doi.org/10.12793/jkscpt.2007.15.1.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kang, Ju Wan, and Jaechun Lee. "Bepotastine-induced urticaria, cross-reactive with other antihistamines." Asia Pacific Allergy 6, no. 4 (2016): 253. http://dx.doi.org/10.5415/apallergy.2016.6.4.253.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Yadav, Neha, Sumit Sachdeva, Manisha Rathi, Sonia Chhabra, Shreay Vashisth, and Dinkar Yadav. "Comparison of efficacy of topical bepotastine besilate and alcaftadine in patients with vernal keratoconjunctivitis." Indian Journal of Clinical and Experimental Ophthalmology 10, no. 2 (2024): 319–24. http://dx.doi.org/10.18231/j.ijceo.2024.057.

Full text

Abstract:

To compare efficacy of bepotastine besilate (1.5%) versus alcaftadine (0.25%) in patients with vernal keratoconjunctivitis.This comparative, randomized, single-blind and prospective study was conducted on 100 patients diagnosed with VKC, who were allocated to receive either of the two treatment groups. Group A received Alcaftdine eye drops once daily, while Group B received bepotastine besilate twice daily for 8 weeks. The efficacy assessment was done at baseline and then at 4 and 8 weeks post-treatment using following parameters - Primary endpoints included clinical symptoms score and clinica

APA, Harvard, Vancouver, ISO, and other styles

30

Carrillo-Martin, Ismael, Alexei Gonzalez-Estrada, and Ves Dimov. "Bepotastine besilate for the treatment of perennial allergic rhinitis." Expert Opinion on Pharmacotherapy 19, no. 15 (2018): 1727–30. http://dx.doi.org/10.1080/14656566.2018.1519020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lee, Sung-Hoon. "Development of an Oral Gastroretnetive Formulation Containing Bepotastine Besilate." Journal of the Korea Academia-Industrial cooperation Society 26, no. 3 (2025): 176–86. https://doi.org/10.5762/kais.2025.26.3.176.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Berelli, Srilekha, Sachin Daigavane, and Pradeep Kumar Panigrahi. "A study on the clinical presentations and treatment response to different therapies in seasonal allergic conjunctivitis." Journal of Clinical Ophthalmology and Research 13, no. 2 (2025): 198–204. https://doi.org/10.4103/jcor.jcor_1_25.

Full text

Abstract:

Purpose: The purpose is to study the clinical presentation of seasonal allergic conjunctivitis (SAC) and treatment response to different therapies. Methods: This hospital-based comparative study included all patients aged over 10 years old diagnosed with SAC. Comprehensive ophthalmic evaluation was done in all cases. The various symptoms and signs were graded according to their severity. Based on the treatment received, the patients were divided into three groups: Group A (bepotastine besilate), Group B (loteprednol etabonate), and Group C (carboxymethylcellulose). The patients were followed u

APA, Harvard, Vancouver, ISO, and other styles

33

Naveen, Kumar, Kumari Asha, and Kumari Kanchan. "Assessing Efficacy and Safety of Olopatadine 0.1% Ophthalmic Solution and Bepotastine 1.5% Ophthalmic Solution in Patients with Vernal Keratoconjunctivitis." International Journal of Current Pharmaceutical Review and Research 16, no. 3 (2024): 185–89. https://doi.org/10.5281/zenodo.12784890.

Full text

Abstract:

Aim: The purpose of the present study was intended to compare the effectiveness and safety of olopatadine 0.1%ophthalmic drops and bepotastine besilate 1.5% ophthalmic drops with BD administration to relieve the symptomsof VKC in a tertiary care hospital in Bihar region.Methods: The study was done in the Department of Pharmacology, DMCH, Laheriasarai, Darbhanga, Bihar,India for duration of 10 months. By simple randomization (odd/even number) method, registered patients weregrouped into A and B. Group A and Group B were given olopatadine 0.1% ophthalmic drops and bepotastinebesilate 1.5% ophtha

APA, Harvard, Vancouver, ISO, and other styles

34

TAKAHASHI, Hidetoshi, and Hajime IIZUKA. "Usefulness and Safety of Bepotastine Besilate for Pruritic Skin Disorders." Nishi Nihon Hifuka 68, no. 3 (2006): 284–87. http://dx.doi.org/10.2336/nishinihonhifu.68.284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

KOHDA, Futoshi, Masutaka FURUE, and Shinichi IMAFUKU. "Immediate Clinical Effectiveness of Bepotastine Besilate for Patients with Urticaria." Nishi Nihon Hifuka 68, no. 5 (2006): 544–47. http://dx.doi.org/10.2336/nishinihonhifu.68.544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Choi, Y. K., Y. H. Chung, Y. S. Nam, et al. "UPLC-MS/MS Method for Determination of Bepotastine in Human Plasma." Journal of Chromatographic Science 52, no. 8 (2013): 886–93. http://dx.doi.org/10.1093/chromsci/bmt135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ha, Tae Hee, Kwee-Hyun Suh, and Gwan Sun Lee. "A Novel Synthetic Method for Bepotastine, a Histamine H1 Receptor Antagonist." Bulletin of the Korean Chemical Society 34, no. 2 (2013): 549–52. http://dx.doi.org/10.5012/bkcs.2013.34.2.549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Garge, Lajri, and Ravindranath B. Saudagar. "Development and Characterization of In Situ Ophthalmic Gel of Bepotastine Besilate." Journal of Drug Delivery and Therapeutics 9, no. 4-A (2019): 656–63. http://dx.doi.org/10.22270/jddt.v9i4-a.3547.

Full text

Abstract:

The aim of the present work was development and characterization of in-situ Ophthalmic Gel of Bepotastine Besilate to overcome the drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. Carbopol 934 and HPMC K100. Carbopol 934 were used as gelling agent and HPMC K100 were used as bioadhesive polymer. The in situ gelling system involves sol-to-gel transition in the cul-de-sac upon instillation to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations were evaluated for Clarity, pH, Viscosity, Bioad

APA, Harvard, Vancouver, ISO, and other styles

39

Lindstrom, Richard L. "The Expanding Picture of the Clinical Utility of BEPREVE® (Bepotastine Besilate Ophthalmic Solution) 1.5 % in the Treatment of Itch Associated with Allergic Conjunctivitis." US Ophthalmic Review 04, no. 02 (2011): 101. http://dx.doi.org/10.17925/usor.2011.04.02.101.

Full text

Abstract:

A new analysis of pivotal trial data and a variety of additional studies completed since US Food and Drug Administration (FDA) approval are broadening our understanding of the clinical utility of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5 % in the treatment of ocular itch associated with allergic conjunctivitis. These results include evidence of a durable therapeutic response of up to 16 hours following a single dose, a comfort profile comparable or superior to other drugs in the class, and robust efficacy against ocular itching and redness in an environmental exposure study model

APA, Harvard, Vancouver, ISO, and other styles

40

Zhang, Chaowei, Chengqun Han, Lili Sun, Jinlong Yu, and Qiaogen Zou. "Identification, Characterization and HPLC Quantification of Process-Related Impurities in Bepotastine Besilate Bulk Drug." Drug Research 70, no. 01 (2019): 12–22. http://dx.doi.org/10.1055/a-0831-2401.

Full text

Abstract:

AbstractBepotastine besilate (here after referred to as BTST), chemically known as ({d(S)4[4[(4chlorophenyl) (2pyridyl) methoxy] piperidino} butyric acid monobenzene sulphonate), is a second-generation antihistamine drug. To the best of our knowledge, no studies concerning the isolation or identification of process-related impurities have been reported so far. The current study reports the development and validation of a stability-indicating RP-HPLC method for the separation and identification of 5 potential impurities in bepotastine besilate. In this experiment, the structures of 3 process-re

APA, Harvard, Vancouver, ISO, and other styles

41

FURUMURA, Minao, Yumiko KUBOTA, and Juichiro NAKAYAMA. "Efficacy and Safety of Bepotastine Besilate in the Treatment of Chronic Urticaria." Nishi Nihon Hifuka 68, no. 1 (2006): 69–75. http://dx.doi.org/10.2336/nishinihonhifu.68.69.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tanizaki, Hideaki, Akihiko Ikoma, Miyuki Fukuoka, Yoshiki Miyachi, and Kenji Kabashima. "Effects of Bepotastine and Fexofenadine on Histamine-Induced Flare, Wheal and Itch." International Archives of Allergy and Immunology 158, no. 2 (2012): 191–95. http://dx.doi.org/10.1159/000330663.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Nakahara, Takeshi, Kazunori Urabe, Yoichi Moroi, Keisuke Morita, and Masutaka Furue. "Bepotastine besilate rapidly inhibits mite-antigen induced immediate reactions in atopic dermatitis." Journal of Dermatological Science 32, no. 3 (2003): 237–38. http://dx.doi.org/10.1016/s0923-1811(03)00130-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Askarkar, Sonali Suresh, and Krishna Radheshyam Gupta. "Design and Evaluation of Ophthalmic Delivery of Bepotastine Besilate From Eye Drop." Pharmaceutical Methods 7, no. 2 (2016): 104–11. http://dx.doi.org/10.5530/phm.2016.7.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Williams, Jon I., James A. Gow, Sharon M. Klier, Shannon L. McCue, Anne Marie F. Salapatek, and Timothy R. McNamara. "Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate." Current Medical Research and Opinion 26, no. 10 (2010): 2329–38. http://dx.doi.org/10.1185/03007995.2010.486753.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Matsui, Nobuaki, Noriyuki Ishihara, Yuri Mochizuki, Hiroki Tamaki, Nobuhiro Nishimura, and Kohji Naora. "Inhibitory Effect on Rituximab-induced Infusion Reaction by Premedication with Fexofenadine or Bepotastine." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 45, no. 7 (2019): 396–403. http://dx.doi.org/10.5649/jjphcs.45.396.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Berdy, Gregg J., and Heather S. Oliff. "Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis." Expert Review of Ophthalmology 5, no. 5 (2010): 595–602. http://dx.doi.org/10.1586/eop.10.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

OHTA, Nobuo, Kazutoshi INAMURA, Daisuke NODA, et al. "The Effect of Prophylactic Treatment with Bepotastine in Patients with Japanese Cedar Pollinosis." Practica Oto-Rhino-Laryngologica 95, no. 5 (2002): 531–37. http://dx.doi.org/10.5631/jibirin.95.531.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lim, Duck Soo, Yoo Seok Youn, Seung Jun Kwack, et al. "Comparative Efficacy and Bioequivalence of Novel H1-Antihistamine Bepotastine Salts (Nicotinate and Salicylate)." Journal of Toxicology and Environmental Health, Part A 77, no. 22-24 (2014): 1451–66. http://dx.doi.org/10.1080/15287394.2014.955833.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Parekh, Jai G. "Evaluating Clinical Perceptions of a New Medication for Ocular Itch Associated with Allergic Conjunctivitis—Results of the Bepreve® 1.5% First Experience Field Survey." US Ophthalmic Review 04, no. 01 (2011): 69. http://dx.doi.org/10.17925/usor.2011.04.01.69.

Full text

Abstract:

Allergic conjunctivitis associated with seasonal or perennial allergy is an increasingly prevalent complaint. Patients seeking professional evaluation for symptoms of ocular allergy usually have exhausted over-the-counter options and expect rapid, effective relief from the treatment prescribed. With the introduction of Bepreve® (bepotastine besilate ophthalmic solution) 1.5%, a survey of US doctors was conducted to evaluate their opinions and impressions of the medication following the initial patient trial. Responses from 427 practitioners, representing a total of 7,340 patient experiences, s

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!